The Dario Blood Glucose Monitoring System consists of the Dario Blood Glucose Test Strips. Dario Glucose Control Solutions and the Dario App as the display component of the Dario Blood Glucose Monitoring System. The Dario Blood Glucose Monitoring System is intended for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips. The Dario Blood Glucose Monitoring System is intended to be used by a single person and should not be shared.

The Dario Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home to monitor the effectiveness of diabetes control. The Dario Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use.

The Dario Blood Glucose Test Strips are for use with the Dario Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip.

The Dario Glucose Control Solutions are for use with the Dario Blood Glucose Meter and the Dario Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.

Device Description

The Dario Blood Glucose Monitoring System is intended for the quantitative measurement of glucose (sugar) in fresh capillary whole blood. The Dario is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home to monitor the effectiveness of diabetes control.

The Dario Blood Glucose Monitoring System consists of a device housing that includes a blood glucose meter and lancing device. The system also includes test strips, lancets, control solutions and a mobile application. The Dario meter does not require coding or separate batteries. The Dario meter is powered via the 3.5mm audio headphone jack of the smart mobile device. Users are instructed to insert the test strip into the meter, apply the blood or control solution to the test strip, after which the meter will process the test in approximately six (6) seconds and display the test result on the smart mobile device screen via the mobile application.

The Dario Blood Glucose Monitoring System uses Apple's iOS smart mobile device technology to view the glucose test results via a mobile application. This application is available for download via the smart mobile device's application store.

Test Principle:

The Dario Blood Glucose Monitoring System is an in vitro diagnostic device intended for the measurement of glucose in fresh whole capillary blood. The principle of the test relies upon a reaction between a specific type of sugar (glucose) in the blood sample and the glucose oxidase in the test strip. This reaction generates a small electrical current, which is measured by the meter. The meter calculates the blood glucose level based on an internal algorithm. The Dario application displays the test result via the smart mobile device display.

AI/ML Overview

Here's an analysis of the acceptance criteria and study detailed in the provided text for the Dario Blood Glucose Monitoring System, structured according to your request:

Acceptance Criteria and Device Performance

A key study for glucose monitoring systems is System Accuracy. The ISO 15197:2003 standard defines acceptance criteria for system accuracy. The device performance is reported against this standard.

Acceptance Criteria (ISO 15197:2003 for System Accuracy)	Reported Device Performance (Dario Blood Glucose Monitoring System)
For glucose concentrations < 75 mg/dL: At least 95% of the individual glucose results shall fall within ± 15 mg/dL of the reference method results.	System Accuracy Study: 100% of individual glucose results fell within 15 mg/dL of the YSI reference at glucose concentrations < 75 mg/dL. User Performance Study: 100% of individual glucose results fell within ± 15 mg/dL for glucose concentrations less than 75 mg/dL (11 out of 11 samples).
For glucose concentrations ≥ 75 mg/dL: At least 95% of the individual glucose results shall fall within ± 20% of the reference method results.	System Accuracy Study: 99.6% of individual glucose results fell within 20% of the results of YSI at glucose concentrations ≥ 75mg/dL. User Performance Study: 98.88% of individual glucose results fell within ± 20% for glucose concentrations greater than or equal to 75 mg/dL (88 out of 89 samples).
Precision/Repeatability: - CV ≤ 5% at blood glucose concentrations ≥ 100 mg/dL - Standard Deviation ≤ 5 mg/dL at blood glucose concentrations <100 mg/dL (typical industry expectation based on similar standards for repeatability, though not explicitly stated with these exact numbers in the provided text as 'acceptance criteria')	Precision/Repeatability Study: CV ≤ 4% at blood glucose concentrations ≥ 100 mg/dL and a standard deviation of ≤ 3 mg/dL at blood glucose concentrations <100 mg/dL. (This meets and exceeds typical precision expectations).
Linearity: A high correlation (R^2 value close to 1) between the device and reference method over the claimed measuring range.	Linearity Study: R^2 value of 0.998, demonstrating that the Dario Blood Glucose Meter is linear over the claimed blood glucose measuring range of 20-600 mg/dL.
Hematocrit Study: Acceptable bias relative to the reference method within the claimed hematocrit range.	Hematocrit Study: The % biases relative to the reference method were acceptable within the claimed hematocrit range of 20% to 60%.
Operating Conditions Study: Accurate results over the claimed temperature and humidity range.	Operating Conditions Study: Demonstrated that the Dario Blood Glucose Monitoring System produces accurate results over the claimed temperature range of 50-113°F (10-45°C) and claimed humidity range of 10-90%.
Altitude Study: Acceptable bias and performance at the claimed altitude.	Altitude Study: The results demonstrate acceptable bias and indicate acceptable performance at the claimed altitude of 10,000 feet.
Interference Study: No significant interference (within ± 10% difference in glucose measurement) from commonly found interfering substances at specified concentrations.	Interference Study: Defined 'no significant interference' as within ± 10% difference in glucose measurement. Limiting concentrations for various compounds (Ascorbic Acid, Uric Acid, Acetaminophen, Total bilirubin, Triglycerides, Cholesterol, Galactose, Ibuprofen, Lactose, Maltose, Methyl-DOPA, Xylose) were established and added to the labeling.

Study Details

Here's the breakdown of the study details as requested, based on the provided text:

Sample Size used for the test set and the data provenance:
- System Accuracy Study: 100 samples with glucose concentrations ranging from 24 to 479 mg/dL.
  - Data Provenance: Not explicitly stated (e.g., country of origin). The text refers to "venous whole blood samples" and "capillary whole blood samples" which implies human biological samples. The study is prospective in the sense that the device was tested against these samples as part of its performance validation.
- Precision/Repeatability Study:
  - Within-run: Venous whole blood samples spiked to five different glucose concentration ranges. 10 repeats for each level, 3 test strip lots, 10 meters, totaling 300 results per glucose level.
  - Between-day: Three levels of glucose control solutions. Each sample measured with 3 test strip lots and 10 meters, over 10 days, totaling 300 results per glucose level.
- Linearity Study: Six test strip lots and 17 glucose concentration samples. Each level measured in replicates of five using three test strip lots.
- Hematocrit Study: Venous whole blood samples with 11 different hematocrit levels, spiked to three glucose concentrations. Tested using 10 Dario meters and three lots of test strips.
- Operating Conditions Study: Five meters and three test strip lots. Five glucose levels of venous blood samples tested.
- Altitude Study: Capillary whole blood samples with glucose concentrations ranging between 49 to 424 mg/dL. Three different test strip lots and six Dario meters.
- User Performance Study:
  - Glucose concentrations < 75 mg/dL: 11 samples.
  - Glucose concentrations ≥ 75 mg/dL: 89 samples.
  - Data Provenance: Not explicitly stated, but implies human users testing blood samples (likely capillary whole blood from fingertips based on the device's indications for use).
- Interference Study: Venous blood spiked with two levels of glucose concentrations, further spiked with varying levels of potentially interfering substances.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- The ground truth in all these studies was established using a "reference method," specifically mentioned as the YSI reference for the System Accuracy Study.
- For blood glucose meters, the reference method (like YSI) itself is a highly accurate laboratory instrument. The "experts" in this context are the trained laboratory personnel operating these reference instruments, not medical professionals providing clinical diagnoses.
Adjudication method for the test set:
- Not applicable as the ground truth is established by a highly accurate laboratory reference instrument (YSI) which provides a direct quantitative measurement. There is no subjective interpretation requiring adjudication among multiple human readers.
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No, this is not an MRMC study. The Dario Blood Glucose Monitoring System is a standalone in-vitro diagnostic device that provides a direct numerical reading. It does not involve human "readers" interpreting images or data that an AI might assist with. Therefore, the concept of "human readers improve with AI vs without AI assistance" is not applicable here.
If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:
- Yes, the device's core performance (e.g., System Accuracy, Precision, Linearity, Hematocrit, Operating Conditions, Altitude, Interference studies) was evaluated in a standalone manner against a reference method. The "algorithm only" aspect refers to the meter calculating the glucose level based on the electrochemical reaction; human interaction is limited to taking the sample and initiating the test. The "User Performance Study" does involve human users, but it's evaluating the system's accuracy when operated by lay users, not an "AI algorithm" in the conventional sense.
The type of ground truth used:
- Reference Method: Exclusively the "YSI reference" (or similar highly accurate laboratory method) for glucose measurement. This is considered a gold standard for in vitro glucose determination.
The sample size for the training set:
- The provided text describes performance validation studies. Information about the specific "training set" for the device's internal algorithm is not provided. Blood glucose meters typically use pre-calibrated sensor technology and algorithms developed through extensive R&D, but the details of that training data (if any in the "machine learning" sense) are not part of this 510(k) summary focused on post-development performance testing.
How the ground truth for the training set was established:
- As noted above, details regarding a "training set" for the algorithm are not provided. For this type of electrochemical device, the "ground truth" for calibration and algorithm development would be established through highly accurate laboratory reference methods (like YSI) for various glucose concentrations.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features the department's name arranged in a circular fashion around a symbol. The symbol consists of a stylized caduceus-like design, with three human profiles facing right, representing health and human services.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

December 21, 2015

LABSTYLE INNOVATIONS LTD. TRACEY WIELINSKI OFFICIAL CORRESPONDENT 3521 HATWYNN RD. CHARLOTTE NC 28269

Re: K150817

Trade/Device Name: Dario Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: II Product Code: NBW. CGA. JJX Dated: November 20, 2015 Received: November 23, 2015

Dear Tracey Wielinski:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Katherine Serrano -S

For : Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known)

K150817

Device Name

Dario Blood Glucose Monitoring System

Indications for Use (Describe)

The Dario Blood Glucose Test Strips are for use with the Dario Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip.

Type of Use (Select one or both, as applicable)
	Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary

(As required by 21.CFR.807.92)

1. SUBMITTER

Manufacturer:	LabStyle Innovation Ltd.9 Halamish St.North Industrial ParkCaesarea 389000, Israel
Contact Person:	Tracey WielinskiQualtra Consulting, Inc.5 Casie LanePepperell, MA 01463USA
	Phone: (440) 915-5833Email: tracey@qualtraconsulting.com
Date Prepared:	December 10, 2015

2. DEVICE INFORMATION

Device Name:	Dario® Blood Glucose Monitoring System
Common Name:	Blood Glucose Test System
Classification Name:	System, Test, Blood Glucose, Over The Counter

Regulation Section	Classification	Product Code	Panel
21 CFR § 862.1345	Class II	CGA, Glucose Oxidase,glucose	ClinicalChemistry(75)
21 CFR § 862.1345	Class II	NBW, system, test, bloodglucose, over the counter	ClinicalChemistry(75)
21 CFR § 862.1660	Class I	JJX, Single (Specified)Analyte Controls (Assayedand Unassayed)	ClinicalChemistry(75)

{4}------------------------------------------------

3. PREDICATE DEVICE

K131230 - Philosys Inc., Gmate SMART Blood Glucose Monitory System, Gmate SMART Application

4. DEVICE DESCRIPTION

Test Principle:

5. INDICATIONS FOR USE

The Dario Blood Glucose Monitoring System consists of the Dario Blood Glucose Meter, Dario Glucose Test Strips, Dario Glucose Control Solutions and the Dario App as the display component of the Dario Blood Glucose Monitoring System. The Dario Blood Glucose Monitoring System is intended for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips. The Dario Blood Glucose Monitoring System is intended to be used by a single person and should not be shared.

{5}------------------------------------------------

The Dario Blood Glucose Test Strips are for use with the Dario Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip.

6. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE

The indications for use and the base scientific technology of the Dario Blood Glucose Monitoring System are both similar to that of the predicate device. Both the subject device and the predicate are in vitro diagnostic devices intended for the measurement of glucose in capillary blood. Thev each use amperometry as the detection method and glucose oxidase as the enzyme in the test strip. Both the subject and predicate device use a smart mobile device to obtain power for the meter via the 3.5mm audio jack and display the blood glucose result in a mobile application.

The test principle for the Dario Blood Glucose Monitoring System and the predicate device are also similar. The principle of the test relies upon a reaction between glucose in the blood sample and the glucose oxidase in the test strip to produce a small electrical current. The meter measures this electrical current and calculates the blood glucose level via an internal algorithm. The Dario and the predicate both use the smart mobile device for the display of the results via a downloadable mobile application.

The performance testing data demonstrated that the subject device does not raise any new issues of safety and effectiveness. Therefore, based on the information provided in this submission, LabStyle Innovations concludes that the Dario Blood Glucose Monitoring System is substantially equivalent to the predicate device.

7. PERFORMANCE TESTING SUMMARY

The following performance data were provided in support of the substantial equivalence determination.

Software Verification and Validation Testing

Software verification and validation testing were conducted as recommended by FDA's Guidance for Industry and FDA Staff. "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." The software for this device was considered as a "moderate" level of concern, since a malfunction or a latent design flaw in the software device could lead to an erroneous result or a delay in delivery of appropriate medical care that would likely lead to minor injury.

Electrical safety and electromagnetic compatibility (EMC)

Electrical safety and EMC testing were conducted on the Dario Blood Glucose Monitoring System. The system complies with IEC 61010-1 and EN 61010-2-101 standards for safety and EN 61326-1 and EN 61326-2-6 standards for EMC.

{6}------------------------------------------------

The Dario Blood Glucose Monitoring System also complies with IEC 60601-1-2.

System Accuracy

System accuracy was determined according to ISO 15197:2003. The Dario Blood Glucose Monitoring System performance was assessed against a reference method. 100 samples with glucose concentrations ranging from 24 to 479 mg/dL were obtained and then tested with three (3) test strip lots and six (6) Dario meters with a total of 600 tests performed. Five (5) low concentration samples ranging of less than 50 mg/dL and five (5) high concentration samples of greater than 400 mg/dL were assessed.

The results showed that 100% of individual glucose results fell within 15 mg/dL of the YSI reference at glucose concentrations < 75 mg/dL and 99.6% of individual glucose results fell within 20% of the results of YSI at glucose concentrations ≥ 75mg/dL.

Precision/Repeatability Study

Precision was determined according to ISO 15197:2003. Within-run precision studies using venous whole blood samples spiked to five (5) different glucose concentration ranges (30 to 50, 51 to 110, 111 to 150, 151 to 250, and 251 to 400 mg/dL). Three (3) Dario test strips lots were tested with 10 different Dario meters and at 10 repeats, for a total of 300 results per glucose level. Between-day precision was evaluated using three (3) levels of glucose control solutions with concentrations of 30 to 50, 96 to 144, and 280 to 420 mg/dL. Per day, each sample was measured with three test strip lots and 10 meters. These tests were performed over 10 days, for a total of 300 results per glucose level.

The results for measurement repeatability and intermediate measurement precision evaluation showed a CV ≤ 4% at blood glucose concentrations ≥ 100 mg/dL and a standard deviation of ≤ 3 mg/dL at blood glucose concentrations <100 mg/dL.

Linearity Study

Linearity was determined according to ISO 15197:2003. Linearity was evaluated using six (6) test strip lots and 17 glucose concentration samples compared against the reference method measurements. Each level was measured in replicates of five (5) using three (3) test strip lots and the values from the Dario Blood Glucose Monitoring System were compared with those obtained from the reference method.

Results showed an R2 value of 0.998, demonstrating that the Dario Blood Glucose Meter is linear over the claimed blood glucose measuring range of 20-600 mg/dL.

Hematocrit Study

The effect of different hematocrit levels on the performance of the Dario Blood Glucose Monitoring System was evaluated according to ISO 15197:2003. Venous whole blood samples with hematocrit levels of 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, and 65% spiked to three (3) glucose concentrations of 50-70. 100-200. and 250-350 mg/dL were used in the assessment. Each sample was then tested using 10 Dario Blood Glucose Meters and three (3) lots of test strips. The values were compared with those obtained from the reference method.

{7}------------------------------------------------

The % biases relative to the reference method were acceptable within the claimed hematocrit range of 20% to 60%.

Operating Conditions Study

Dario BGMS operating condition was evaluated at different temperatures and humidity levels. The combined effect of temperature and humidity were evaluated in a chamber where these conditions can be controlled. The study used five (5) meters and three (3) test strip lots. Five (5) glucose levels of venous blood samples with approximate concentrations of 60, 100, 300, 480 mg/dL were tested under the following conditions:

12+2 . 15±5% (low temperature, low humidity)

12±2,85±5% (low temperature, high humidity)

20±2,15±5% (medium temperature, low humidity)

20+2 . 90% (medium temperature, high humidity)

43±2,15±5% (high temperature, low humidity)

43±2,85±5% (high temperature, high humidity)

The results demonstrated that the Dario Blood Glucose Monitoring System produces accurate results over the claimed temperature range of 50-113°F (10-45°C) and claimed humidity range of 10-90%.

Sample Volume Study

A sample volume study was performed with the Dario Blood Glucose Monitoring System to verify the test strip sample volume requirement since the Dario requires less blood to measure glucose values as compared to the predicate device. The results support the claimed sample volume of 0.3uL.

Environmental Testing

Testing was performed to test the mechanical resistance to shock, vibration and impact; equipment temperature exposure limits; and equipment humidity exposure of the Dario Blood Glucose Monitoring System. The system complies with the requirements in IEC 60068 and ISO 15197.

Disinfection Efficacy Study

A disinfection efficacy study for the exterior surfaces of the Dario Blood Glucose Meter was conducted. The results showed inactivation of hepatitis B virus (HBV) with the chosen disinfectant, Super Sani-Cloth Wipes (EPA Registration Number 9480-4).

Cleaning and Disinfection Robustness Study

Cleaning and disinfection studies were performed demonstrating that there was no change in system performance or in the wear of the external materials of the meter and the housing after 156 cleaning and disinfection cycles designed to simulate three (3) years of single-patient device use (the life of the product). The test strips were assessed for performance impacts after a total of 25 cleaning cycles of the test strip cartridge.

Altitude Study

{8}------------------------------------------------

Capillary whole blood samples with glucose concentrations ranging between 49 to 424 mg/dL were tested on the Dario Blood Glucose Monitoring System at 10,152 feet altitude and compared to a reference method. The study evaluated three (3) different test strip lots and six (6) Dario meters.

The results demonstrate acceptable bias and indicate acceptable performance at the claimed altitude of 10,000 feet.

User Performance Study

A User Performance evaluation was performed to evaluate the accuracy of blood glucose level results obtained by users with the Dario when compared to a reference method. The secondary endpoint was to evaluate the ease of use of the subject device by lay users. Acceptance criteria were based on the requirements of ISO 15197:2003.

The results of the User Performance Evaluation study are described below:

Results for glucose concentrations less than 75 mg/dL:

Within ± 5%	Within ± 10%	Within ± 15%
4/11	9/11	11/11
(36.36%)	(81.82%)	(100%)

Results for glucose concentrations greater than or equal to 75 mg/dL:

Within ± 5%	Within ± 10%	Within ± 15%	Within ± 20%
39/89	68/89	85/89	88/89
(43.82%)	(76.40%)	(95.51%)	(98.88%)

Interference Study

Interference studies on the subject device were performed by spiking venous blood with two (2) levels of glucose concentrations then testing these samples on the subject device and with a reference method. Both of the glucose spike venous samples were spiked with varying levels of potentially interfering substances, and then analyzed with the Dario Blood Glucose Meter and a reference method. The % difference between the mean of the measurements from the subject device and the reference method was then calculated. No significant interference was defined as within ± 10% difference in glucose measurement when compared to the reference methods.

The limiting concentrations of these substances have been added to the labeling and are listed below:

Compounds	System Limitations (mg/dL)
Ascorbic Acid	> 4
Uric Acid	> 11
Acetaminophen	> 6
Total bilirubin	> 35
Triglycerides	> 810
Cholesterol	> 455
Galactose	> 60

{9}------------------------------------------------

Ibuprofen	> 50
Lactose	> 25
Maltose	> 120
Methyl-DOPA	> 2
Xylose	> 50

Bench and Clinical Testing Summary

The design verification and validation testing of the subject device was performed in accordance with ISO 15197:2003. The Dario Blood Glucose Monitoring System met all system acceptance criteria.

8. CONCLUSION

The performance testing data demonstrates that the Dario Blood Glucose Monitoring System is substantially equivalent to the legally marketed predicate device. The Dario Blood Glucose Monitoring System does not raise any new questions of safety and effectiveness. Therefore, based on the information provided in this submission, it can be concluded that the Dario Blood Glucose Monitoring System has demonstrated substantial equivalence to the predicate device.

Regulation Number and Section

§ 862.1345 Glucose test system.

(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.